I
ntra-alveolar activation of the coagulation cascade is thought to lead to the deposition of fibrin in the pulmonary interstitium and alveoli. [1] [2] [3] [4] Fibrin deposition, in turn, may directly increase vascular permeability and may serve as a matrix for collagen formation. 5 Fibrin and its degradation products potentiate inflammation by modulating chemotaxis and endothelial cell injury. 6 In some lung diseases, histologic studies have demonstrated that areas of fibrin deposition correspond with sites of subsequent fibrosis. 7 The coagulation and fibrinolytic systems also have been implicated in the pathogenesis of sarcoidosis. Hasday et al 8 noted enhanced expression of procoagulant activity in BAL fluid in patients with sarcoidosis, while Kobayashi et al 9 demonstrated that protein C activity was decreased in BAL fluid from subjects with sarcoidosis. Finally, the degree of cell-associated procoagulant activity in alveolar macrophages from subjects with sarcoidosis has been shown to correlate with the radiographic stage of the disease. 2 D dimer (DD) results from the breakdown of fibrin and can serve as a marker for fibrinolytic system activity. Additionally, circulating DD can be measured easily. DD levels have been shown to correlate with disease activity in both systemic lupus erythematosus and Crohn's disease. 10, 11 Because of the significance of fibrinolysis in sarcoidosis coupled with the relationship between DD and disease activity in disorders potentially similar to sarcoidosis, we hypothesized that DD would correlate with various markers that are used frequently to clinically assess disease activity in sarcoidosis. To test this hypothesis, we conducted a prospective study evaluating circulating DD in consecutive patients with newly diagnosed sarcoidosis.
Materials and Methods

Subjects
Consecutive patients seen in our pulmonary clinic between June 1997 and June 1999 with newly diagnosed sarcoidosis were eligible to participate in this study. The diagnosis of sarcoidosis was based on the histologic demonstration of nonnecrotizing granulomas with special stains that fail to reveal either fungal or mycobacterial organisms. Exclusion criteria included the following: age Ͻ 18 years; a clinical diagnosis of sarcoidosis without histologic confirmation; and treatment with corticosteroids (oral or inhaled) within the preceding 12 months. Patients were considered newly diagnosed if they were enrolled in the study within 7 days of referral for evaluation for sarcoidosis. Our institution is a tertiary care, university-affiliated military medical center. The study was approved by the Walter Reed Army Medical Center Human Use Committee, and each subject provided written informed consent.
Study Protocol
Patients had DD measured by a latex agglutination assay (Wellcotest; Murex Diagnostics; London, England). A titer of Ͼ 1:2 was considered a positive DD. Per the manufacturer, in healthy individuals, the circulating DD level measured by this test is Ͻ 1:2, which correlates with an approximate DD level of 1 to 2 g/mL. The DD was interpreted by a technician blinded to the patient's clinical data. Subjects also underwent a standard evaluation that included a history and physical examination, a chest radiograph (CXR), pulmonary function tests (PFTs) with measurement of the single-breath diffusing capacity of carbon monoxide (Dlco), and an ECG. Radiographic stage of disease was defined as follows: stage 0, normal CXR; stage I, bilateral hilar lymphadenopathy alone; stage II, bilateral hilar lymphadenopathy with interstitial infiltrates; and stage III, interstitial infiltrates alone. The PFTs and Dlco were interpreted in accordance with the guidelines of the American Thoracic Society. 12 Normal values were derived from Crapo et al, 13, 14 and corrections for race were made. 14 The Dlco was corrected for hemoglobin. Values for PFTs and Dlco were considered abnormal if they fell outside the 95% confidence interval (CI) for the predicted values. The erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) level, and angiotensin converting enzyme (ACE) level were also measured. All subjects had normal liver function as measured by both prothrombin time and liver-associated enzymes. The presence of pulmonary symptoms (dyspnea, chest pain, and cough) was determined from a questionnaire completed by all subjects on enrollment.
Statistical Analysis
Patients who were positive for DD (DDϩ) were compared to those lacking DD (DDϪ) for the variables noted above. The Student's t test was used for continuous variables. The 2 test was employed to compare categoric variables except in cases when expected values were small. In these instances, we relied on the Fisher's Exact Test. The distribution of CXR stages was analyzed via the Wilcoxon rank sum test. All tests were two-tailed, and a p value of Ͻ 0.05 was assumed to represent statistical significance. Ninety-five percent CIs are reported where appropriate. Analyses were performed using computer software (SPSS, version 7.0; SPSS Inc; Chicago, IL).
For sample size determination, we assumed that the incidence of DD in the study population would be approximately 40%. Using this and controlling the ␣ error at 0.05, we calculated that the study would require 27 patients in order to have an 80% power to detect a 12% difference in FVC between the DDϩ and DDϪ subjects. A 12% difference in FVC was chosen because we thought that this degree of variance would be clinically significant.
Results
During the study period, 31 patients were evaluated for suspected sarcoidosis. In two patients, bronchoscopy was nondiagnostic, and the patients declined further evaluation. For one subject, the eventual diagnosis was not sarcoidosis. Thus, the final study cohort consisted of 28 individuals. As shown in Table 1 , the mean (Ϯ SD) age of the cohort was 38.2 Ϯ 5.4 years, 64.3% of subjects were men, and 67.9% were African American. The most common radiographic appearance noted in the study group was stage I disease, which was seen in 20 patients (71.4%). DD was positive in 39.3% of all subjects (95% CI, 22.1 to 59.3%). Ten patients were referred for evaluation of incidentally noted, asymptomatic bilateral hilar adenopathy. Only one of these patients was DDϩ, while nine lacked circulating DDs (p ϭ 0.041).
DDϩ patients did not differ significantly from DDϪ patients with respect to demographic variables. A majority of patients in each cohort were men. Likewise, 81.8% of DDϩ individuals were African Americans compared to 52.9% of DDϪ subjects (p ϭ 0.226). The mean ages of the two cohorts were also similar (37.9 vs 38.8 years, respectively; p ϭ 0.835). The incidence of extrapulmonary involvement did not differ between the two groups. One DDϩ subject had lupus pernio, while a DDϪ patient presented with uveitis.
DD status did correlate significantly with the radiographic stage of disease (p ϭ 0.035). For example, 6 of 20 patients with stage I CXRs were DD positive, while 4 of 6 patients with stage II sarcoidosis were DDϩ. Interestingly, as Figure 1 demonstrates, DD was more commonly seen in patients with radiographic evidence of interstitial involvement (stages II and III). DDϩ individuals were 3.8 times more likely to have interstitial involvement as seen on CXR. Also, patients with circulating DD reported dyspnea more often (p ϭ 0.034). The presence of other pulmonary symptoms (chest pain and cough) did not differ between the two cohorts.
As with radiographic stage and dyspnea, the Dlco differed significantly between DDϩ patients and DDϪ patients ( Table 3 ). The mean Dlco in DDϩ patients was significantly lower (57.2% predicted vs 70.5% predicted, respectively; p ϭ 0.026). Other spirometric measures did not separate DDϩ patients from DDϪ patients. Analyzed by PFT pattern, nine (81.8%) of the DDϩ patients had normal PFTs. Similarly, 11 DDϪ patients (64.7%) had normal PFTs.
The serum ACE level was significantly higher in DDϩ patients. As Table 3 demonstrates, the mean ACE level was 47.9 Ϯ 23.1 IU/L in DDϩ patients, while it was 25.9 Ϯ 15.3 IU/L in DDϪ patients (p ϭ 0.006). We further analyzed ACE as a categoric rather than a continuous variable to determine the frequency of elevated levels in the two cohorts. This analysis revealed that ACE levels were more often abnormally high in DDϩ patients. The ACE level was elevated in seven DDϩ patients (63.6%) but in only two DDϪ patients (11.8%) (p ϭ 0.01). In terms of other inflammatory markers (Table 3) , the ESR was higher in DDϩ patients, but this difference was not statistically significant. There was also no difference between the two groups with respect to the CRP level.
Discussion
This prospective study found that DD was often positive in patients with newly diagnosed sarcoidosis. The presence of circulating DD suggests that the fibrinolytic system is active in patients with sarcoidosis and that it may be associated with disease activity as assessed by CXR, dyspnea, Dlco, and ACE level. Our findings confirm and add to previous studies focusing on the coagulation system in sarcoidosis. However, most prior work has relied on BAL fluid rather than on serum markers of fibrinolysis. Our use of an easily measured serum marker of fibrinolysis in sarcoidosis is significant in that BAL is not routinely performed in the evaluation and management of patients with sarcoidosis and that reliance on BAL may miss inflammatory activity outside of the lung.
Previous studies of coagulation in patients with sarcoidosis have shown that the BAL fluid of these patients contains elevated concentrations of protein C. 9 Concomitantly, the BAL levels of activated protein C bound to its inhibitor are lower in patients with sarcoidosis. 9 Sensitive markers of coagulation activation, such as thrombin-antithrombin III complex, are also higher in BAL fluid from subjects with sarcoidosis. 9 Other mediators and markers of coag- ulation, such as thromboplastin and fibrin degradation products, are increased in BAL fluid obtained from subjects with sarcoidosis. 15 In addition to the acellular components of BAL fluid, alveolar macrophages demonstrate enhanced procoagulant activity. Chapman et al 2 found that tissue factor activity in alveolar macrophages from patients with sarcoidosis was nearly three times higher than in control subjects. More importantly, studies of this type that have specifically focused on markers of pulmonary disease severity in sarcoidosis and procoagulant activity have reported a positive relationship between the two. 2, Hasday et al 8 noted that the ratio of procoagulant activity to plasminogen activator levels correlated with the degree of alveolitis measured by BAL fluid, while Chapman et al 2 reported that only patients with either stage II or III sarcoidosis had elevated tissue factor activity.
One prior study has examined DD in sarcoidosis. In this study of only 10 patients, Perez et al 16 found that DD was present in the BAL fluid of 8 subjects and that they could detect DD in serum from 7 patients. The DD status of BAL fluid correlated with the cellularity and the percentage of lymphocytes in the BAL fluid. They further hypothesized that circulating DD might serve as a marker for disease activity. Our work expands on these preliminary observations in several significant ways. First, the larger sample size of the present study and its reliance on consecutive, never-treated subjects strengthens the validity of our conclusions. With a greater number of subjects, our study had increased power to detect clinically important relationships. Furthermore, by not using a cross-sectional design, our findings are less likely to have been affected by selection bias. Second, we focused on measures routinely used in the evaluation and management of patients with sarcoidosis. The association between CXR stage, PFTs, pulmonary symptoms, and serum markers of inflammation and DD status has not been explored previously. Third, the fact that we observed significant differences in multiple end points based on DD status underscores the strength of these findings and implies that our findings are unlikely to have resulted from systematic error and that DD serves as a marker for a common underlying pathophysiologic process or may result from a more general activation of the inflammatory process. The nexus among symptoms, CXR, and Dlco further highlights that DD may be clinically useful in the management of patients. This hypothesis, however, requires formal testing, but our results suggest that such trials will be of value.
Our study has several limitations. The majority of patients in this study were men, and sarcoidosis, epidemiologically, is seen more frequently in women. 17 With respect to other demographic variables, though, our study cohort was similar to the typical sarcoidosis population in the United States and consisted of young African Americans with predominantly stage I disease seen on CXRs. We also employed a latex agglutination assay. Latex agglutination assays, unlike enzyme-linked immunosorbent assay based systems, must be read visually and provide titer levels rather than numeric values. Our decision to use this latex agglutination assay was based on the fact that when the study was designed this particular assay was the most widely available tool for measuring DD and also was one of the least expensive. Finally, we focused on FVC rather than on total lung capacity (TLC). FVC is only an approximation of TLC, and, thus, we may have failed to detect differences in lung volumes when, in fact, they existed. FVC when normal, though, excludes restriction as measured by TLC with a negative predictive value of nearly 98%. Therefore, since the majority of patients in our study had normal or near-normal FVC levels, it is unlikely that direct measurement of the TLC would have altered our findings. 18 In conclusion, DD is frequently positive in patients with sarcoidosis. This implies that the coagulation system is active in these patients. The question of whether DD results from a general stimulation of various inflammatory cascades or represents a more specific pathophysiologic process requires further investigation. DD status also is associated with interstitial involvement as measured by CXR, the presence of dyspnea, a lower Dlco, and an elevated ACE level. Because of these relationships, DD may serve as a marker for disease activity in sarcoidosis.
